Home » Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals
Array BioPharma Licenses Cancer Drug ARRY-543 to ASLAN Pharmaceuticals
ASLAN Pharmaceuticals and Array BioPharma announced a license agreement to develop Array’s HER2/EGFR inhibitor, ARRY-543, currently entering Phase II development for solid tumors.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May